Diabetic Foot Ulcers - Pipeline Review, H2 2016

Date: November 23, 2016
Pages: 157
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: D232529D726EN
Leaflet:

Download PDF Leaflet

Diabetic Foot Ulcers - Pipeline Review, H2 2016
Diabetic Foot Ulcers - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Foot Ulcers – Pipeline Review, H2 2016, provides an overview of the Diabetic Foot Ulcers (Metabolic Disorders) pipeline landscape.

Diabetic foot ulcers are sores that occur on the feet of people with Type 1 Diabetes and Type 2 Diabetes. Symptoms include sores, ulcers, or blisters on the foot or lower leg, pain, walking with difficulty, discoloration in feet: black, blue, or red, cold feet and fever, skin redness or swelling, or other signs of infection. The predisposing factors include diabetic neuropathy, peripheral vascular disease, a foot deformity and history of tobacco use disorder.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Foot Ulcers – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Foot Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 16, 5, 16, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Diabetic Foot Ulcers.

Diabetic Foot Ulcers (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Diabetic Foot Ulcers (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Diabetic Foot Ulcers (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Foot Ulcers (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Diabetic Foot Ulcers (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Diabetic Foot Ulcers (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Diabetic Foot Ulcers Overview
Therapeutics Development
Pipeline Products for Diabetic Foot Ulcers - Overview
Pipeline Products for Diabetic Foot Ulcers - Comparative Analysis
Diabetic Foot Ulcers - Therapeutics under Development by Companies
Diabetic Foot Ulcers - Therapeutics under Investigation by Universities/Institutes
Diabetic Foot Ulcers - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Diabetic Foot Ulcers - Products under Development by Companies
Diabetic Foot Ulcers - Products under Investigation by Universities/Institutes
Diabetic Foot Ulcers - Companies Involved in Therapeutics Development
ANP Technologies Inc
CardioVascular BioTherapeutics Inc
Celgene Corp
Chrysalis BioTherapeutics Inc
CytoTools AG
EyeGene Inc
FirstString Research Inc
Genentech Inc
GlaxoSmithKline Plc
Human Stem Cells Institute
Izun Pharmaceuticals Corp
Karyopharm Therapeutics Inc
Lakewood-Amedex Inc
Lytix Biopharma AS
Mallinckrodt Plc
MediWound Ltd
NovaLead Pharma Pvt Ltd
Oneness Biotech Co Ltd
Osiris Therapeutics Inc
Pherecydes Pharma SA
Plurogen Therapeutics Inc
TechnoPhage SA
TGV-Laboratories
Theravasc Inc
Topadur Pharma AG
USV Pvt Ltd
viDA Therapeutics Inc
ViroMed Co Ltd
Diabetic Foot Ulcers - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
3K3A-APC - DRUG PROFILE
ALLO-ASC - Drug Profile
ANP-017 - Drug Profile
AP-102 - Drug Profile
APO-2 - Drug Profile
becaplermin biosimilar - Drug Profile
Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural Ulcer - Drug Profile
Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers - Drug Profile
CL-05 - Drug Profile
CODA-001 - Drug Profile
CVBT-141B - Drug Profile
Cyndacel-M - Drug Profile
daprodustat - Drug Profile
EG-Decorin - Drug Profile
epidermal growth factor biosimilar - Drug Profile
EscharEx - Drug Profile
esmolol hydrochloride - Drug Profile
Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile
Granexin - Drug Profile
Heberprot-P - Drug Profile
IMSP-001 - Drug Profile
IZN-6D4 - Drug Profile
LTX-109 - Drug Profile
MT-003 - Drug Profile
Mul-1867 - Drug Profile
Neovasculgen - Drug Profile
Nu-2 - Drug Profile
Nu-3 - Drug Profile
ON-101 - Drug Profile
OTI-1501 - Drug Profile
PDA-002 - Drug Profile
PluroGel N - Drug Profile
PP-2351 - Drug Profile
Recombinant Protein for Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile
RG-7880 - Drug Profile
rusalatide acetate - Drug Profile
selinexor - Drug Profile
sodium nitrite SR - Drug Profile
Stathmin-1 - Drug Profile
TOPN-53 - Drug Profile
TP-102 - Drug Profile
V-10 - Drug Profile
VM-202 - Drug Profile
VTI-1000 Series - Drug Profile
VTI-3000 Series - Drug Profile
Diabetic Foot Ulcers - Dormant Projects
Diabetic Foot Ulcers - Discontinued Products
Diabetic Foot Ulcers - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 154

LIST OF TABLES

Number of Products under Development for Diabetic Foot Ulcers, H2 2016
Number of Products under Development for Diabetic Foot Ulcers - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2016
Diabetic Foot Ulcers - Pipeline by ANP Technologies Inc, H2 2016
Diabetic Foot Ulcers - Pipeline by CardioVascular BioTherapeutics Inc, H2 2016
Diabetic Foot Ulcers - Pipeline by Celgene Corp, H2 2016
Diabetic Foot Ulcers - Pipeline by Chrysalis BioTherapeutics Inc, H2 2016
Diabetic Foot Ulcers - Pipeline by CytoTools AG, H2 2016
Diabetic Foot Ulcers - Pipeline by EyeGene Inc, H2 2016
Diabetic Foot Ulcers - Pipeline by FirstString Research Inc, H2 2016
Diabetic Foot Ulcers - Pipeline by Genentech Inc, H2 2016
Diabetic Foot Ulcers - Pipeline by GlaxoSmithKline Plc, H2 2016
Diabetic Foot Ulcers - Pipeline by Human Stem Cells Institute, H2 2016
Diabetic Foot Ulcers - Pipeline by Izun Pharmaceuticals Corp, H2 2016
Diabetic Foot Ulcers - Pipeline by Karyopharm Therapeutics Inc, H2 2016
Diabetic Foot Ulcers - Pipeline by Lakewood-Amedex Inc, H2 2016
Diabetic Foot Ulcers - Pipeline by Lytix Biopharma AS, H2 2016
Diabetic Foot Ulcers - Pipeline by Mallinckrodt Plc, H2 2016
Diabetic Foot Ulcers - Pipeline by MediWound Ltd, H2 2016
Diabetic Foot Ulcers - Pipeline by NovaLead Pharma Pvt Ltd, H2 2016
Diabetic Foot Ulcers - Pipeline by Oneness Biotech Co Ltd, H2 2016
Diabetic Foot Ulcers - Pipeline by Osiris Therapeutics Inc, H2 2016
Diabetic Foot Ulcers - Pipeline by Pherecydes Pharma SA, H2 2016
Diabetic Foot Ulcers - Pipeline by Plurogen Therapeutics Inc, H2 2016
Diabetic Foot Ulcers - Pipeline by TechnoPhage SA, H2 2016
Diabetic Foot Ulcers - Pipeline by TGV-Laboratories, H2 2016
Diabetic Foot Ulcers - Pipeline by Theravasc Inc, H2 2016
Diabetic Foot Ulcers - Pipeline by Topadur Pharma AG, H2 2016
Diabetic Foot Ulcers - Pipeline by USV Pvt Ltd, H2 2016
Diabetic Foot Ulcers - Pipeline by viDA Therapeutics Inc, H2 2016
Diabetic Foot Ulcers - Pipeline by ViroMed Co Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Diabetic Foot Ulcers - Dormant Projects, H2 2016
Diabetic Foot Ulcers - Dormant Projects (Contd..1), H2 2016
Diabetic Foot Ulcers - Dormant Projects (Contd..2), H2 2016
Diabetic Foot Ulcers - Dormant Projects (Contd..3), H2 2016
Diabetic Foot Ulcers - Discontinued Products, H2 2016 146

LIST OF FIGURES

Number of Products under Development for Diabetic Foot Ulcers, H2 2016
Number of Products under Development for Diabetic Foot Ulcers - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Ask Your Question

Diabetic Foot Ulcers - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: